Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial)

Antiviral Therapy

Volumn 12, Issue 3, 2007, Pages 417-422

  Molina, Jean Michel ^a   Journot, Valérie ^b,c   Furco, André ^a   Palmer, Pierre ^a   De Castro, Nathalie ^a   Raffi, François ^d   Morlat, Philippe ^e   May, Thierry ^f   Rancinan, Corinne ^b,c   Chêne, Geneviève ^b,c  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d HÔTEL DIEU   (France)

^e HÔPITAL SAINT ANDRÉ   (France)

^f CHU NANCY BRABOIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; EMTRICITABINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; VIRUS RNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FOOT PAIN; GASTROINTESTINAL SYMPTOM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIPODYSTROPHY; LONG TERM CARE; LYMPHOCYTE COUNT; MALE; MENTAL CONCENTRATION; MULTICENTER STUDY; NIGHTMARE; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTIGO;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CHOLESTEROL; DEOXYCYTIDINE; DIDANOSINE; DRUG TOLERANCE; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; LIPIDS; LIPOPROTEINS; MALE; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249047434     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-29.
3. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodefiency virus-infected patients. J Infect Dis, 2000; 182:599-602.
4. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients. J Am Med Assoc 2004, 292:180-190.
5. Molina JM, Journot V, Morand-Joubert L, et al. Simplification Therapy with Once-Daily Emtricitabine, Didanosine, and Efavirenz in HIV-1-Infected Adults with Viral Suppression Receiving a Protease Inhibitor-Based Regimen: A Randomized Trial. J Infect Dis 2005; 191:830-839.
6. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8-11 February 2004. Abstract 570.
7. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
8. De Jesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviral naïve HIV-infected adults. Clin Infect Dis 2004, 39:1038-1046.
9. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J Am Med Assoc 2004; 292:191-201.
10. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011-1019.
11. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13:125-131.
12. Chene G, Angelini E, Cotte L, et al. Role of long-term nucleoside analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34:649-657.
13. Molina JM, Marcelin AG, Pavie J, et al. AI454-176 JAGUAR Study Team. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis 2005; 191:840-847.
14. Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naïve patients: 4 year follow-up study. AIDS 2004; 18:775-779.
15. Gulick RM, Meibohm A, Havlir D, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine and lamivudine. AIDS 2003; 17:2345-2349.
16. rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, 24-27 July 2005. WePe16.7B04.
17. Tashima K, Staszewski S, Nelson M, et al. Durable viral suppression on EFV-based HAART: 168 weeks of follow-up. XV International AIDS Conference. Bangkok, Thailand, 11-16 July 2004. Poster TuPe B457.
18. Hirsch MS, Steigbigel RT, Staszewski S, et al. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naïve adults with advanced HIV infection. Clin Infect Dis 2003; 37:1119-1124.
19. th European Conference on Clinical Aspects and Treatment of HIV infection. Athens, Greece, 28-31 October 2001. Abstract LB10.